Latest papers

MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.

MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.

Urticarial hypersensitivity reaction caused by temozolomide.

[A case of metastatic paratesticular rhabdomyosarcoma in an adult successfully treated with multidrug combination chemotherapy].

Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?

Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide.

Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.

Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential.

Successful treatment of metastatic malignant fibrous histiocytoma of the kidney.

Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.

Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme.

Stratifying osteosarcoma: minimizing and maximizing therapy.

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.

Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review.

Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.

Gene expression profiling predicts response to temozolomide in malignant gliomas.

Triazenoindazoles and triazenopyrazolopyridines: design, synthesis, and cytotoxic activity.

Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.

[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].

Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.